Boston Scientific gets panel nod for Taxus

Interventional device developer Boston Scientific of Natick, MA, reports that the Circulatory System Devices Panel has unanimously recommended U. S. Food and Drug Administration approval for the firm’s Taxus Express2 paclitaxel-eluting coronary stent system

The panel provides the FDA with independent professional expertise and technical assistance on the development, safety and efficacy, and regulation of medical devices. A final decision on approval will be made by the FDA, said Boston Scientific.

By staff writers
November 21, 2003

Related Reading

Biophan joins forces with Boston Scientific, November 5, 2003

Boston Scientific adds to Rubicon investment, October 30, 2003

Q3 gains reported at Boston Scientific, October 22, 2003

FDA sets date to review Boston Scientific stent, September 16, 2003

Boston Scientific releases Taxus clinical results, September 16, 2003

Copyright © 2003

Page 1 of 180
Next Page